NO20062369L - Anvendelse av et pyrazoldedvat for fiemstilling av medikamenter for a hindre og behandle dyslipideml og sykdommer assosiert med dyslipidemi og/eller fedme - Google Patents

Anvendelse av et pyrazoldedvat for fiemstilling av medikamenter for a hindre og behandle dyslipideml og sykdommer assosiert med dyslipidemi og/eller fedme

Info

Publication number
NO20062369L
NO20062369L NO20062369A NO20062369A NO20062369L NO 20062369 L NO20062369 L NO 20062369L NO 20062369 A NO20062369 A NO 20062369A NO 20062369 A NO20062369 A NO 20062369A NO 20062369 L NO20062369 L NO 20062369L
Authority
NO
Norway
Prior art keywords
dyslipidemia
obesity
manufacture
medications
diseases associated
Prior art date
Application number
NO20062369A
Other languages
English (en)
Inventor
Jean-Marc Herbert
Michele Arnone
Philip Janiak
Mohammed Bensaid
Hassan Massound Heshmati
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/FR2004/002715 external-priority patent/WO2005046689A2/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20062369L publication Critical patent/NO20062369L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en kannabinoidreseptor CBi antagonstisk forbindelse, nevnte forbindelse er avledet fra pyrazol og anvendes alene eller assosiert med en annen aktiv ingrediens for fremstilling av medikamenter for hindring og behandling av dyslipidemi og sykdommer assosiert med dyslipidemi og/eller fedme, slik som metabolittisk syndrom, kardiovaskulære risikoer og hepatiske sykdommer.
NO20062369A 2003-10-24 2006-05-24 Anvendelse av et pyrazoldedvat for fiemstilling av medikamenter for a hindre og behandle dyslipideml og sykdommer assosiert med dyslipidemi og/eller fedme NO20062369L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312553A FR2861300B1 (fr) 2003-10-24 2003-10-24 Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
PCT/FR2004/002715 WO2005046689A2 (fr) 2003-10-24 2004-10-22 Utilisation d’un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l’obesite

Publications (1)

Publication Number Publication Date
NO20062369L true NO20062369L (no) 2006-05-24

Family

ID=34400824

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062369A NO20062369L (no) 2003-10-24 2006-05-24 Anvendelse av et pyrazoldedvat for fiemstilling av medikamenter for a hindre og behandle dyslipideml og sykdommer assosiert med dyslipidemi og/eller fedme

Country Status (4)

Country Link
CN (1) CN1893946A (no)
FR (1) FR2861300B1 (no)
NO (1) NO20062369L (no)
ZA (1) ZA200604178B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102416015B (zh) * 2011-08-23 2013-02-27 南京正宽医药科技有限公司 一种含他汀类药物的组合物及其用途
CN110237070A (zh) * 2019-05-10 2019-09-17 辽宁大学 厄贝沙坦在制备降血脂药物中的应用
CN112007156A (zh) * 2019-05-30 2020-12-01 复旦大学 大麻素受体药物在制备治疗心肌细胞坏死性凋亡药剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
UA78523C2 (en) * 2001-09-21 2007-04-10 Solvay Pharm Bv 4,5-dihydro-1h-pyrazoie derivatives as cb1 antagonists
CA2478183C (en) * 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
AU2003226149A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
NZ537251A (en) * 2002-07-09 2007-02-23 Bristol Myers Squibb Co Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives

Also Published As

Publication number Publication date
FR2861300A1 (fr) 2005-04-29
CN1893946A (zh) 2007-01-10
ZA200604178B (en) 2008-07-30
FR2861300B1 (fr) 2008-07-11

Similar Documents

Publication Publication Date Title
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
AR063550A2 (es) Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20083562L (no) Cannabinoidreseptormodulatorer
WO2005000820A3 (fr) Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
WO2008043544A8 (en) Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2008040361A3 (en) Use of a combination of hypothermia inducing drugs
WO2007009724A3 (en) Cycloalkane-substituted pyrazoline derivatives, their preparation and use as medicaments
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
TW200631945A (en) The aromatic amide derivatives, the pharmaceutical composition comprising the same and its medical application
WO2009124552A3 (en) Use of a combination of hypothermia inducing drugs
WO2008116663A3 (en) Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
WO2005076761A3 (en) Composition for preenting a cold
NO20062369L (no) Anvendelse av et pyrazoldedvat for fiemstilling av medikamenter for a hindre og behandle dyslipideml og sykdommer assosiert med dyslipidemi og/eller fedme
WO2007006790A3 (en) Combination of a dpp-iv inhibitor and a cannabinoid cb1 receptor antagonist
WO2009071096A3 (en) Combination of medical and physical cooling treatment of ischemic effects
MX2009008176A (es) Derivados de tetrahidro-naftaleno sustituidos con heterociclos, su preparacion y su uso como medicamentos.
TW200626167A (en) Sophorae Radix extract for prevention and treatment of respiratory diseases
NO20074768L (no) Anvendelse av pyrazolderivater for fremstilling av medisiner nyttige for a forebygge eller behandle nyresykdommer
NO20080066L (no) Farmasoytiske preparater av mikronisert (4-klorfenyl) [4-(4-pyridylmetyl)ftalazin-1-yl] og salter derav, med umiddelbar frigivelse og hoyt legemiddelinnhold
NO20074609L (no) Nye forbindelser avledet fra 5-tioksylose og terapeutisk anvendelse derav
UY28576A1 (es) Utilización de un derivado de pirazol para la preparación de medicamentos utiles para la prevención y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application